文献速递生殖医学

来曲唑与枸橼酸氯米芬治疗多囊卵巢综合征的比较:系统综述与Meta分析

Letrozole Compared With Clomiphene Citrate for Polycystic Ovarian Syndrome: A Systematic Review and Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2023-02-02

该系统综述与Meta分析检索截至2022年2月1日的多个数据库,纳入29项随机对照试验、3952名不孕合并多囊卵巢综合征女性及7633个促排卵周期,比较来曲唑与枸橼酸氯米芬的促排卵效果。汇总分析显示来曲唑在排卵率(RR 1.14,95%CI 1.06-1.21,P<.001)、临床妊娠率(RR 1.48,95%CI 1.34-1.63,P<.001)和活产率(RR 1.49,95%CI 1.27-1.74,P<.001)方面优于枸橼酸氯米芬。作者推荐来曲唑优于枸橼酸氯米芬作为不孕合并多囊卵巢综合征女性的促排卵药物,尽管证据质量参差不齐。

要点

  • 来曲唑组排卵率高于枸橼酸氯米芬组(RR 1.14,95%CI 1.06-1.21,P<.001)。
  • 来曲唑组临床妊娠率高于枸橼酸氯米芬组(RR 1.48,95%CI 1.34-1.63,P<.001)。
  • 来曲唑组活产率高于枸橼酸氯米芬组(RR 1.49,95%CI 1.27-1.74,P<.001)。

核心结论

  • 来曲唑与改善的排卵率、妊娠率和活产率相关,优于枸橼酸氯米芬。
  • 作者推荐来曲唑优于枸橼酸氯米芬作为不孕合并多囊卵巢综合征女性的促排卵药物,尽管证据质量参差不齐。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE through PubMed、Web of Science、EMBASE、Cochrane Library和ClinicalTrials.gov从建库至2022年2月1日。
  • 纳入报告不孕合并多囊卵巢综合征女性接受来曲唑或枸橼酸氯米芬后行定时性交或宫腔内人工授精的排卵诱导结局的随机对照试验。
  • 共纳入29项随机对照试验,包括3952名女性和7633个排卵诱导周期。
  • 数据收集和整理遵循2020年PRISMA声明。

主要发现

  • 排卵率证据来自22项随机对照试验,来曲唑组优于枸橼酸氯米芬组(RR 1.14,95%CI 1.06-1.21,P<.001)。
  • 临床妊娠率证据来自28项随机对照试验,来曲唑组优于枸橼酸氯米芬组(RR 1.48,95%CI 1.34-1.63,P<.001)。
  • 活产率证据来自8项随机对照试验,来曲唑组优于枸橼酸氯米芬组(RR 1.49,95%CI 1.27-1.74,P<.001)。

关键数值与推荐

  • 排卵率:RR 1.14,95%CI 1.06-1.21,P<.001,以来曲唑组与枸橼酸氯米芬组比较。
  • 临床妊娠率:RR 1.48,95%CI 1.34-1.63,P<.001,以来曲唑组与枸橼酸氯米芬组比较。
  • 活产率:RR 1.49,95%CI 1.27-1.74,P<.001,以来曲唑组与枸橼酸氯米芬组比较。

临床怎么用

  • 作者推荐来曲唑优于枸橼酸氯米芬作为不孕合并多囊卵巢综合征女性的促排卵药物,尽管证据质量参差不齐。

局限性

  • 证据质量参差不齐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effect of letrozole and clomiphene citrate in women with infertility and polycystic ovarian syndrome (PCOS). METHODS OF STUDY SELECTION: MEDLINE through PubMed, Web of Science, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched for relevant studies from inception to February 1, 2022. Two reviewers retrieved, filtered, and extracted data independently using the bibliographic software EndNote X9 and Excel workbook. We included randomized controlled trials (RCTs) reporting ovulation induction outcomes in women with infertility and PCOS treated with either letrozole or clomiphene citrate followed by timed intercourse or intrauterine insemination. The data were merged into a mean difference or risk ratio (RR) with 95% CI, depending on variable types. TABULATION, INTEGRATION, AND RESULTS: Data collection and organization were conducted in accordance with the 2020 PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) statement. Twenty-nine RCTs were eligible, which included 3,952 women and 7,633 ovulation induction cycles. We acquired evidence from 22 RCTs for the ovulation rate, 28 RCTs for the clinical pregnancy rate, and eight RCTs for live-birth rate. Pooled analysis indicated that letrozole treatment prevailed against clomiphene citrate in ovulation rate (RR 1.14, 95% CI 1.06-1.21, P <.001), clinical pregnancy rate (RR 1.48, 95% CI 1.34-1.63, P <.001), and live-birth rate (RR 1.49, 95% CI 1.27-1.74, P <.001). CONCLUSIONS: Letrozole was associated with improved ovulation, pregnancy, and live-birth rates compared with clomiphene citrate. We recommend letrozole over clomiphene citrate as an ovulation induction drug in women with infertility and PCOS, although the quality of the evidence is mixed. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42022308777.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Liu Z, Geng Y, Huang Y, et al. Letrozole Compared With Clomiphene Citrate for Polycystic Ovarian Syndrome: A Systematic Review and Meta-analysis. Obstet Gynecol. 2023. PMID: 36735392. doi:10.1097/AOG.0000000000005070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。